Use of stathmin as a biomarker of drug response to furazanobenzimidazoles

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9366682
APP PUB NO 20130345263A1
SERIAL NO

13979955

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BASILEA PHARMACEUTICA AG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bachmann, Felix Basel, CH 26 46
Lane, Heidi Alexandra Therwil, CH 9 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 14, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00